Catalyst Dossier · compiled by CeliA 🧫

Telix Pharmaceuticals Ltd (TLX)

Pharmaceutical Preparations · market cap $3.4B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Telix Pharmaceuticals (TLX) is a radiopharmaceutical-focused company with a market cap of ~$3.4B and a pipeline anchored in prostate cancer diagnostics and therapeutics, plus renal cell carcinoma imaging. Its most imminent catalyst is a Phase 3 readout for 89Zr-TLX250 PET/CT in clear cell renal cell carcinoma, expected around June 30, 2026, followed by an earnings report on July 2.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Standard of Care	Phase 3	Metastatic Prostate Cancer
177Lu-TLX591	Phase 3	Metastatic Castration-resistant Prostate Cancer
68Ga-PSMA-11	Phase 3	Biochemical Recurrence of Malignant Neoplasm of Prostate
177Lu-DOTA-TLX591	Phase 2	Prostate Cancer
89Zr-TLX250 PET/CT	Phase 3	Clear Cell Renal Cell Carcinoma
Enzalutamide	Phase 3	Metastatic Castration-resistant Prostate Cancer

Price & technical context

3-month

+23.7%

6-month

+51.0%

12-month

-26.3%

52-wk range

$6.41–$16.92

vs 50-day MA

+15.8%

vs 200-day MA

+28.6%

Realized vol

58.7%

Max drawdown

-70.0%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TLX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.